[144] Quest Diagnostics Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Quest Diagnostics (DGX) shows a proposed sale of 4,532 common shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $829,356.00 and an approximate sale date of 08/19/2025. The shares were acquired on 08/19/2025 under options originally granted 02/18/2020 and payment is indicated as cash. The filer also reported two recent sales by the same person: 5,535 shares on 08/06/2025 for $968,625.00 and 1,975 shares on 08/15/2025 for $355,499.90. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

• Full Rule 144 disclosure provided including broker, share counts, market value, and acquisition details
• Recent sales reported with gross proceeds, increasing transparency about insider transactions

Negative

• Insider sales totaling 7,510 shares in August 2025 could be perceived negatively by some investors despite no disclosed material nonpublic information
• No 10b5-1 plan adoption date provided in the visible remarks, leaving plan reliance unclear

Insights

Securities Analyst

TL;DR: Routine insider sale of option-derived shares; transaction appears procedural rather than indicative of company performance.

The filing documents an insider selling 4,532 shares derived from previously granted options, with contemporaneous cash payment and execution via a broker on the NYSE. Recent completed sales totaling 7,510 shares in August 2025 are disclosed, with aggregate reported proceeds of $1,324,124.90. For investors, this is a transparent disclosure of insider liquidity but does not by itself provide evidence of operational change or material information about Quest Diagnostics.

Corporate Governance Expert

TL;DR: Filing meets Rule 144 disclosure requirements; includes required seller attestation and trading plan language.

The notice contains required elements: securities class, broker, number of shares, market value, acquisition details, and recent sales. It also includes the seller's attestation regarding material nonpublic information and a placeholder for 10b5-1 plan adoption date. From a governance perspective, the document demonstrates compliance with insider trading disclosure norms but does not disclose a 10b5-1 plan date or other mitigating governance context.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	4532	829356.00	111823441	08/19/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/19/2025	Options Granted 02/18/2020	Issuer			4532	08/19/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Thomas Plewman 500 Plaza Drive Secaucus NJ 07094	Common	08/06/2025	5535	968625.00
Thomas Plewman 500 Plaza Drive Secacucus NJ 07094	Common	08/15/2025	1975	355499.90

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the Form 144 for DGX propose to sell?

The notice proposes sale of 4,532 common shares via Fidelity on the NYSE with aggregate market value $829,356.00 and approximate sale date 08/19/2025.

When were the securities to be sold originally acquired?

The shares were recorded as acquired on 08/19/2025 and are described as options granted 02/18/2020.

Has the filer sold other shares recently?

Yes; the filing reports sales of 5,535 shares on 08/06/2025 for $968,625.00 and 1,975 shares on 08/15/2025 for $355,499.90.

Does the filing state the method of payment?

Yes; payment for the proposed sale is indicated as cash.

Does the Form 144 include a representation about material nonpublic information?

Yes; the person signing the notice represents they do not know any material adverse information about the issuer that has not been publicly disclosed.